Clinical Trials Insight: 700049856
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 12 Oct 2009
At a glance
- Drugs Iobenguane (Primary)
- Indications Paraganglioma; Phaeochromocytoma
- Focus Adverse reactions
- Sponsors Molecular Insight Pharmaceuticals
- 12 Oct 2009 New trial record.
- 02 Oct 2009 12-month efficacy data were presented at the North American Neuroendocrine Tumor Society (NANETS) 2009 Neuroendocrine Tumor Symposium.